The JAVELIN Bladder Medley Trial: Avelumab-Based Combinations as First-Line Maintenance in Advanced Urothelial Carcinoma

References

• Sung H , FerlayJ, SiegelRLet al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. v3.2023.
   Google Scholar
• National Cancer Institute, SEER Cancer Stat Facts: Bladder Cancer. Bethesda, MD, USA. https://seer.cancer.gov/statfacts/html/urinb.html (Accessed 5July2023).
   Google Scholar
• Swami U , GrivasP, PalSK, AgarwalN. Utilization of systemic therapy for treatment of advanced urothelial carcinoma: lessons from real world experience. Cancer Treat. Res. Commun.27, 100325 (2021).
   PubMedGoogle Scholar
• Jensen JB , HaubergDS, DuusHjortsoe M, MadsenME, OlsenJ, AgerbækM. Treatment pattern and overall survival among patients with locally advanced or metastatic urothelial carcinoma: results from a complete nationwide unselected real-world registry study in Denmark from 2010 to 2017. Ann. Oncol.32(Suppl. 5), Abstract 707P (2021).
   Google Scholar
• Niegisch G , GerullisH, LinSWet al. A real-world data study to evaluate treatment patterns, clinical characteristics and survival outcomes for first- and second-line treatment in locally advanced and metastatic urothelial cancer patients in Germany. J. Cancer9(8), 1337–1348 (2018).
   PubMed Web of Science ®Google Scholar
• Powles T , BellmuntJ, ComperatEet al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol.33(3), 244–258 (2022).
   PubMed Web of Science ®Google Scholar
• Cathomas R , LorchA, BruinsHMet al. The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma. Eur. Urol.81(1), 95–103 (2021).
   PubMed Web of Science ®Google Scholar
• Powles T , ParkSH, VoogEet al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N. Engl. J. Med.383(13), 1218–1230 (2020).
   PubMed Web of Science ®Google Scholar
• Heery CR , O’Sullivan-CoyneG, MadanRAet al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a Phase Ia, multicohort, dose-escalation trial. Lancet Oncol.18(5), 587–598 (2017).
   PubMed Web of Science ®Google Scholar
• Boyerinas B , JochemsC, FantiniMet al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol. Res.3(10), 1148–1157 (2015).
   PubMed Web of Science ®Google Scholar
• Bavencio (avelumab) . Prescribing information. EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA (2022).
   Google Scholar
• Bavencio (avelumab). Summary of product characteristics. Merck Europe B.V., Amsterdam, The Netherlands, an affiliate of Merck KGaA (2023).
   Google Scholar
• Powles T , ParkSH, VoogEet al. Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer. Future Oncol.18(19), 2361–2371 (2022).
   PubMed Web of Science ®Google Scholar
• Powles T , ParkSH, CasertaCet al. Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after ≥2 years of follow-up. J. Clin. Oncol.41(19), 3486–3492 (2023).
   PubMed Web of Science ®Google Scholar
• Powles T , SridharSS, LoriotYet al. Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. Nat. Med.27(12), 2200–2211 (2021).
   PubMed Web of Science ®Google Scholar
• Bardia A , HurvitzSA, TolaneySMet al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N. Engl. J. Med.384(16), 1529–1541 (2021).
   PubMed Web of Science ®Google Scholar
• Goldenberg DM , CardilloTM, GovindanSV, RossiEA, SharkeyRM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget.6(26), 22496–22512 (2015).
   PubMedGoogle Scholar
• Goldenberg DM , SharkeyRM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan. MAbs11(6), 987–995 (2019).
   PubMed Web of Science ®Google Scholar
• Xu C , JiangF, HuangHet al. The anti-TIGIT antibody M6223 induces significant anti-tumor efficacy and immune response via multiple mechanisms of action. J. Immunother. Cancer9(Suppl. 2), Abstract 326 (2021).
   Google Scholar
• Miyazaki T , MaitiM, HennessyMet al. NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy. J. Immunother. Cancer9(5), e002024 (2021).
   PubMed Web of Science ®Google Scholar
• Zaman S , JadidH, DensonAC, GrayJE. Targeting Trop-2 in solid tumors: future prospects. Onco. Targets Ther.12, 1781–1790 (2019).
   PubMed Web of Science ®Google Scholar
• Trodelvy (sacituzumab govitecan-hziy). Prescribing information. Gilead Sciences, Inc., Foster City, CA, USA (2023).
   Google Scholar
• Trodelvy (sacituzumab govitecan-hziy). Summary of product characteristics. Gilead Sciences Ireland UC, Carrigtwohill, Co., Cork, Ireland (2023).
   Google Scholar
• Tagawa ST , BalarAV, PetrylakDPet al. TROPHY-U-01: a Phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J. Clin. Oncol.39(22), 2474–2485 (2021).
   PubMed Web of Science ®Google Scholar
• Grivas P , TagawaST, BellmuntJet al. TROPiCS-04: study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy. J. Clin. Oncol.39(Suppl. 6), Abstract TPS498 (2021).
   Web of Science ®Google Scholar
• Grivas P , PouesselD, ParkCHet al. Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy. J. Clin. Oncol.41(Suppl. 6), Abstract 518 (2023).
   Google Scholar
• Huang Z , QiG, MillerJS, ZhengSG. CD226: an emerging role in immunologic diseases. Front. Cell Dev. Biol.8, 564 (2020).
   PubMed Web of Science ®Google Scholar
• Johnston RJ , Comps-AgrarL, HackneyJet al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell26(6), 923–937 (2014).
   PubMed Web of Science ®Google Scholar
• He W , ZhangH, HanFet al. CD155T/TIGIT signaling regulates CD8(+) T-cell metabolism and promotes tumor progression in human gastric cancer. Cancer Res.77(22), 6375–6388 (2017).
   PubMed Web of Science ®Google Scholar
• Hung AL , MaxwellR, TheodrosDet al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. Oncoimmunology7(8), e1466769 (2018).
   PubMed Web of Science ®Google Scholar
• Titov A , SunN, KeltonC, JurzakM, MaH, XuC. Evaluation of novel anti-TIGIT antibody M6223 as a single agent and in combination with avelumab on human natural killer (NK) cell cytotoxicity. J. Immunother. Cancer10(Suppl. 2), Abstract 432 (2022).
   Google Scholar
• Genentech press release . Genentech Reports Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer (2022). https://www.gene.com/media/press-releases/14951/2022-05-10/genentech-reports-interim-results-for-ph (Accessed 5July2023).
   Google Scholar
• Genentech press release . Genentech Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-Stage Small Cell Lung Cancer (2022). https://www.gene.com/media/press-releases/14947/2022-03-29/genentech-provides-update-on-phase-iii-s (Accessed 5July2023).
   Google Scholar
• Rudin CM , LiuSV, LuSet al. SKYSCRAPER-02: primary results of a Phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo)+carboplatin+etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC). J. Clin. Oncol.40(Suppl. 17), Abstract LBA8507 (2022).
   Web of Science ®Google Scholar
• Mettu NB , UlahannanSV, BendellJCet al. A Phase Ia/b open-label, dose-escalation study of etigilimab alone or in combination with nivolumab in patients with locally advanced or metastatic solid tumors. Clin. Cancer Res.28(5), 882–892 (2022).
   PubMed Web of Science ®Google Scholar
• Niu J , Maurice-DrorC, LeeDHet al. First-in-human Phase I study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer. Ann. Oncol.33(2), 169–180 (2022).
   PubMed Web of Science ®Google Scholar
• Cho BC , AbreuDR, HusseinMet al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol.23(6), 781–792 (2022).
   PubMed Web of Science ®Google Scholar
• Kirk P , KuoP, AddepalliMet al. Pre-clinical efficacy and tolerability of NKTR-255, a polymer-conjugated IL-15 for immuno-oncology. J. Immunother. Cancer5(Suppl. 2), Abstract P332 (2017).
   Google Scholar
• Julia EP , AmanteA, PampenaMB, MordohJ, LevyEM. Avelumab, an IgG1 anti-PD-L1 immune checkpoint inhibitor, triggers NK cell-mediated cytotoxicity and cytokine production against triple negative breast cancer cells. Front. Immunol.9, 2140 (2018).
   PubMed Web of Science ®Google Scholar
• Miyazaki T , KivimäeS, HennessyMet al. NKTR-255, a polymer-conjugated IL-15 enhances antibody-dependent cellular cytotoxicity mediated by NK cells in a B cell lymphoma model. Blood134(Suppl. 1), 5302 (2019).
   Google Scholar